Please use this identifier to cite or link to this item:
|Title:||The HPA axis and GABA-Glutamate Systems as Potential Antidepressant Targets in Prostate Cancer||Contributor(s):||Sharpley, Chris (author) ; Christie, David R H (author)||Publication Date:||2011||DOI:||10.2174/1876822901104010001||Handle Link:||https://hdl.handle.net/1959.11/9702||Abstract:||A common treatment for Prostate Cancer includes androgen-deprivation for a period of months prior to radiation or surgery. Some data suggest that this may exacerbate the already elevated depression levels of these patients, arguing for concomitant application of antidepressant therapy. However, the various waves of antidepressants developed in the last 40 years have shown only arguable specific efficacy over placebo, plus significant side-effects which may hinder treatment decision-making and compliance. This paper outlines two emerging and potential pathways for development of new pharmacological agents for depression that hold promise of helping patients to reduce their depressive symptomatology.||Publication Type:||Journal Article||Source of Publication:||Open Prostate Cancer Journal, v.4, p. 1-5||Publisher:||Bentham Open||Place of Publication:||The Netherlands||ISSN:||1876-8229||Field of Research (FOR):||110319 Psychiatry (incl Psychotherapy)||Socio-Economic Outcome Codes:||920199 Clinical Health (Organs, Diseases and Abnormal Conditions) not elsewhere classified||Peer Reviewed:||Yes||HERDC Category Description:||C1 Refereed Article in a Scholarly Journal||Statistics to Oct 2018:||Visitors: 117
|Appears in Collections:||Journal Article|
Files in This Item:
checked on Mar 5, 2019
Items in Research UNE are protected by copyright, with all rights reserved, unless otherwise indicated.